Selected Publications and Presentations at Conferences

The clinical results of NA-831 have been or will be published in medical journals and presented at various international conferences including:


  • *NA-931: A Novel Quadruple IGF-1, GLP-1, GIP, and Glucagon Receptor Agonist Attenuates Alcohol-Mediated Behavior
    • The 6th World Conference on Addiction Medicine and Psychiatry
    November 25-26, 2024 in Paris, FRANCE

  • * First paper: Neurogenesis Hypothesis- Clinical Trials of NA-831 for Alzheimer’s Disease and NA-901 for Major Depressive Disorder
    • and

  • * Second paper: Combination Therapy Phase 3 Protocol: Placebo-Controlled, Double-Blind, Parallel-Group to Study the Safety and Efficacy of NA-831 in Combination with Lecanemab in Subjects with Early Alzheimer's Disease
    • The 17th annual CTAD conference was held in Madrid, SPAIN
    October 29 – November 1, 2024

  • *NA-931, a Novel Quadruple IGF-1, GLP-1 and GIP Receptor Agonist Reduces Body Weight Without Muscle Loss
    • World Obesity and Weight Management
    October 24-26, 2024 | Baltimore, MD, USA

  • * NA-931, a Novel Quadruple IGF-1, GLP-1 and GIP Receptor Agonist for the treatment of obesity
    • International Conference on Obesity and Weight Management
    October 16-17, 2024 | Las Vegas, NV, USA

  • *A novel quadruple receptor agonist NA-931 reduces obesity and improves mash profile in DIO mice
    *A Phase 2 clinical protocol evaluating efficacy and safety of NA-941 in patients with MASH
    • The 10th Paris MASH International Conference- September 5-6, 2024, in Paris, FRANCE

  • *Neurogenesis Hypothesis and NA-901 for the treatment of Major Depressive Disorder
    • Neurology World Conference, September 4-6, 2024 in San Francisco, California, USA

    List of 5 papers at Alzheimer Association International Conference (AAIC)- July 27-August, 2024 in Philadelphia, PA, USA:

  • *Phase 3 Clinical Protocol: Placebo-Controlled, Double-Blind, Parallel-Group to Study Safety and Efficacy of NA-831 in Combination with Lecanemab in Subjects with Early Alzheimer's Disease

    *Phase 2 Clinical Trials of NA-831 for the Treatment of Alzheimer's Disease and Major Depressive Disorder, support the Neurogenesis Hypothesis

    *Associations Between Alzheimer's Disease and Obesity: Clinical Studies of NA-831 for AD and NA-931 for Obesity

    *Associations Between Alzheimer's Disease and Stroke: Clinical Studies of NA-831 for AD and NA-911 for Stroke

    *Amyloid hypothesis: 20 years of failure in Alzheimer’s research
    • Alzheimer Association International Conference (AAIC)-July 27-August, 2024 in Philadelphia, PA, USA

  • *NA-941, a new metabolite of IGF-1 for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH)
    • The 7th Global MASLD Congress, June 24-25, 2024, London UK

  • * Efficacy and Safety of Semaglutide and Tirzepatide: A Comparative Analysis of Clinical Trials
    • American Diabetes Association-84th Scientific Session- June 21-24, 2024 in Orlando, Florida, USA

  • *A Phase 2 Randomized Placebo-Controlled Clinical Trial to Evaluate the Effect of NA-931 on Weight Loss in Obese Adult Subjects
    • American Diabetes Association-84th Scientific Session- June 21-24, 2024 in Orlando, Florida, USA

  • *A Phase 2 Randomized Placebo-Controlled Clinical Trial to Evaluate the Effect of NA-931 on Weight Loss in Obese Adult Subjects
    • American Association of Clinical Endocrinology, May 9-11, 2024 in New Orleans, Louisiana, USA

  • *Phase 2 clinical trials of NA-931, a new IGF-1/ GLP-1 Agonist for the Treatment of Obesity
    • The 4th International Conference on Diabetes, Endocrinology and Obesity- March 11-12, 2024, Rome, ITALY

  • *Neurogenesis Hypothesis and Clinical Trials of NA-831 for the Treatment of Alzheimer’s Disease and Major Depressive Disorder
    • Clinical Trials on Alzheimer’s Disease (CTAD), October 24-27, 2023 in Boston, MA, USA

  • *A Phase 3 Clinical Trial Protocol to Evaluate the Safety & Efficacy of Combination Therapy of Lecanemab and NA-831
    • Clinical Trials on Alzheimer’s Disease (CTAD), October 24-27, 2023 in Boston, MA, USA

  • *Neurogenesis Hypothesis and Clinical Trials of NA-831 for the Treatment of Alzheimer’s Disease and Major Depressive Disorder
    • Presented at Neurology World Conference- September 15-17, 2023 in Miami, Florida, USA

  • *Amyloid Hypothesis & Neurogenesis Hypothesis: A Case Study Of Phase 2A Clinical Trials Of NA- 831 For The Treatment Of Alzheimer's Disease
    • International Conference on Alzheimer’s Disease and Parkinson’s Disease- March 28-April 1, 2023 Gothenburg, SWEDEN

  • *Amyloid hypothesis: the beginning of the end of a dogma
    • The 6th European Congress on Neurology and Brain Disorders- November 17-18, 2022, Rome, ITALY

  • *Neurogenesis Hypothesis: A case-study – Phase 2A clinical trials of NA-831 for the treatment of Alzheimer’s disease
    • Presented at International Conference on Alzheimer’s disease (AD-PD-2022) – March 15-20, 2022 in Barcelona, SPAIN

  • *A Phase 3 Clinical Trial Protocol to Evaluate the Safety and Efficacy of NA-831 in Patients With Early Alzheimer's Disease
    • Presented at Clinical Trials on Alzheimer’s Disease (CTAD) Conference –November 29-December 2, 2022 in San Francisco, CA, USA

  • *Proposing the Neurogenesis Hypothesis for Alzheimer’s Disease with a case study- Phase 2 Clinical trials of NA-831
    • Alzheimer’s and Dementia, 2022;18(Suppl.10):e061573. https://alz-journals.onlinelibrary.wiley.com/doi/10.1002/alz.061573

  • *A Phase 3 Clinical Trial Protocol to Evaluate the Efficacy and Safety of NA-831 in Subjects with Early Onset of Alzheimer’s Disease
    • Alzheimer’s and Dementia, December 20, 2022 https://doi.org/10.1002/alz.069165

  • *A Randomized Double-Blind Placebo-Controlled Phase 2A Clinical Trial of NA-831 in Patients with MCI and Early Onset of Alzheimer's Disease
    • Alzheimer’s and Dementia, July 1, 2019 https://doi.org/10.1016/j.jalz.2019.08.013

    For further information about our products, please contact us. Contact us